First Trimester Aneuploidy Screening Markers in Women with Pre-Gestational Diabetes Mellitus
1
Department of Obstetrics and Gynecology, University of Connecticut Health Center-School of Medicine, Farmington, CT 06032, USA
2
Department of Genetics and Developmental Biology, University of Connecticut Health Center-School of Medicine, Farmington, CT 06032, USA
3
Biostatistics Center, Connecticut Institute for Clinical and Translational Science, University of Connecticut Health Center-School of Medicine, Farmington, CT 06032, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2014, 3(2), 480-490; https://doi.org/10.3390/jcm3020480
Received: 21 February 2014
/
Revised: 18 March 2014
/
Accepted: 19 March 2014
/
Published: 8 May 2014
(This article belongs to the Special Issue Prenatal Genetic Screening and Diagnosis-Part 2)
Objective: To investigate whether maternal serum pregnancy associated plasma protein-A (PAPP-A), total β human chorionic gonadotropin (hCG) levels and nuchal translucency (NT) measurements differ in women with pre-gestational diabetes mellitus (PGDM) compared to non-diabetic controls and to assess whether correction factors are needed for diabetic women in calculation of aneuploidy risks. Study Design: We performed a retrospective study of all women who underwent first trimester aneuploidy screening (11 + 0 to 13 + 6 weeks) from 2005 to 2011. The primary study outcome was the difference in PAPP-A, β-hCG and NT multiples of median between women with PGDM and non-diabetic women. Results: Of 6741 eligible patients, 103 patients with PGDM were using insulin and 4 patients were using oral hypoglycemic agents; the latter were excluded due to small number. There was 12% reduction of median PAPP-A (p = 0.001) and 18% reduction of median hCG (p = 0.006) in women with PGDM receiving insulin. There was no difference in NT. Conclusions: In women with PGDM receiving insulin, PAPP-A and β-hCG levels are significantly lower compared to non-diabetic women. This suggests that when calculating risks for aneuploidy, correction factors should be considered to adjust PAPP-A and β-hCG concentrations to those seen in non-diabetic women.
View Full-Text
Keywords:
re-gestational diabetes; aneuploidy; first trimester screening; PAPP-A; β-hCG; correction factors; HbA1c
▼
Show Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License.
MDPI and ACS Style
Gurram, P.; Benn, P.; Grady, J.; Prabulos, A.-M.; Campbell, W. First Trimester Aneuploidy Screening Markers in Women with Pre-Gestational Diabetes Mellitus. J. Clin. Med. 2014, 3, 480-490. https://doi.org/10.3390/jcm3020480
AMA Style
Gurram P, Benn P, Grady J, Prabulos A-M, Campbell W. First Trimester Aneuploidy Screening Markers in Women with Pre-Gestational Diabetes Mellitus. Journal of Clinical Medicine. 2014; 3(2):480-490. https://doi.org/10.3390/jcm3020480
Chicago/Turabian StyleGurram, Padmalatha, Peter Benn, James Grady, Anne-Marie Prabulos, and Winston Campbell. 2014. "First Trimester Aneuploidy Screening Markers in Women with Pre-Gestational Diabetes Mellitus" Journal of Clinical Medicine 3, no. 2: 480-490. https://doi.org/10.3390/jcm3020480
Find Other Styles
